Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.7 years of cash runway.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | — | -$69M | — | — | -67.6% | -60.2% | -$65M | — | $109M |
| 2024 | — | -$52M | — | — | -35.3% | -29.2% | -$28M | — | $176M |
| 2023 | — | -$60M | — | — | -99.2% | -59.9% | — | — | $100M |
| 2022 | — | -$26M | — | — | 80.3% | -489.1% | — | — | $13785 |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | — | -$26M | — | — | -13.3% | -12.3% | $19M | — | $205M |
| Mar '26 | — | -$24M | — | — | -11.2% | -10.6% | -$19M | — | $226M |
| Dec '25 | — | -$17M | — | — | -16.9% | -15.1% | -$22M | — | $109M |
| Sep '25 | — | -$18M | — | — | -16.4% | -12.5% | -$15M | — | $139M |
| Jun '25 | — | -$16M | — | — | -12.5% | -10.1% | $11M | — | $154M |
| Mar '25 | — | -$17M | — | — | -12.5% | -10.1% | -$11M | — | $171M |
| Dec '24 | — | -$14M | — | — | -9.2% | -7.6% | -$11M | — | $176M |
| Sep '24 | — | -$21M | — | — | -13.4% | -10.9% | -$6M | — | $188M |
| Jun '24 | — | -$10M | — | — | -6.5% | -5.5% | -$7M | — | — |
| Mar '24 | — | -$8M | — | — | -12.4% | -8.6% | -$5M | — | — |
| Dec '23 | — | -$8M | — | — | -13.9% | -8.4% | — | — | $100M |
| Sep '23 | — | -$8M | — | — | -12.8% | -7.9% | — | — | $104M |
| Jun '23 | — | -$34M | — | — | -48.3% | -30.0% | — | — | $113M |
| Mar '23 | — | -$10M | — | — | -34.4% | -21.6% | — | — | $44M |
| Dec '22 | — | $1M | — | — | -3.4% | 20.9% | — | — | $13785 |
| Sep '22 | — | -$1M | — | — | 11.6% | -0.8% | — | — | $74453 |
| Jun '22 | — | -$925000 | — | — | 11.0% | -0.7% | — | — | $220735 |
| Mar '22 | — | $8M | — | — | -99.8% | 5.6% | — | — | $514604 |
| Dec '21 | — | $1M | — | — | — | 0.8% | — | — | $729223 |
| Sep '21 | — | $6M | — | — | — | 4.1% | — | — | $986647 |
See the revenue and net-income charts above for Zura Bio Ltd's multi-year trend.
As of FY2025, Zura Bio Ltd reported — of total debt against $109M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.